FOXO3/TRIM22 axis abated the antitumor effect of gemcitabine in non-small cell lung cancer via autophagy induction

Lung cancer is one of the leading causes of death around the world now. Non-small cell lung cancer (NSCLC) accounts for more than 80% of the total lung cancer (1). Gemcitabine (GEM)-based chemotherapy is the first-line therapeutic approach for the NSCLC treatment (2). However, owing to acquired chemo-resistance, the therapeutic effect is not satisfactory, and the prognosis of NSCLC patients receiving GEM treatment is still poor (3). Based on this, the molecular mechanism underlying chem-resistance requires further investigation to improve the clinical outcomes of NSCLC patients